# Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

> **NCT00084630** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Adult Fibrosarcoma
- Dermatofibrosarcoma Protuberans
- Recurrent Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00084630
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084630, "Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00084630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*